semaglutide
5 Reasons FDA Exclusion Ruins Semaglutide Plans
The FDA’s April 2026 exclusion of semaglutide from the 503B bulk list raises patient costs by up to 25 percent and fragments the supply chain. The rule eliminates the low-cost bulk option that hospitals once relied on, forcing pharmacies to source from higher-priced distributors. Your weight-loss prescription just got